Clinical Trial Search

Primary: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 — 33.3; 6.7; 32.7; 6.1 Percentage of Participants — p=0.0001

Primary: Participants Who Transitioned to Oral Feeding — 23; 24 Participants

Primary: Patient Satisfaction With Pain Management After Surgery — 4; 4; 2.5; 5 score on a scale

Primary: CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio — 0.10; 0.23; 0.12; 0.13 ratio

Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6 — -48.97; -27.75 percentage change — p=<0.0001

Primary: Number of Participants With Continuation of Breastfeeding at 8 Weeks Postpartum — 54; 45; 48; 43 Participants

Primary: The Time Taken to Achieve a TOF Ratio of 0.9 After Administration Sugammadex — 3.13; 2.56; 2.33; 5.00 minutes

Primary: Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE). — 36.5; 60; 40; 21.2 Percentage of participants

Primary: Anterior Chamber Cell Clearing Rate — 119; 95 Participants

Primary: Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to Intensity — 33; 17; 17 Participants

Primary: Adjusted Annualized Relapse Rate (ARR) in Adult Group — 0.018 relapses per participant-year

Primary: Number of Participants With an Adverse Event (AE) — 131 Participants

Primary: Total Amount of Opioid Medications Administered — 0.44; 0.83 MME/kg — p=0.001

Primary: Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL — 60.0 percentage of participants

Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants